Biotage AB (publ)
BIOT.ST
Stockholm Stock Exchange143.20
SEK
+0.20
- -
Biotage AB (publ)
BIOT.ST
(Stockholm Stock Exchange)
Recent
price
143.20
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Biotage AB (publ) is a Sweden-based global life sciences company specializing in the development and supply of advanced systems, consumables, and services for drug discovery, development, and analytical testing. The company operates two primary segments: Drug Discovery and Development, which includes solutions for the synthesis, purification, and isolation of small and large molecules as well as bioprocessing purification; and Analytical Testing, which provides workflow solutions for bioanalytical, forensic toxicology, doping control, environmental, food, and water testing. Biotage's product portfolio includes chromatography resins, flash purification systems (Biotage® Flash 75/150/400 and Isolera LS), automated sample preparation instruments, microwave synthesis technology, peptide synthesis and purification systems, evaporative light-scattering detectors, and consumables such as cartridges, plates, adsorbents, and reagents. Founded in 1975 and headquartered in Uppsala, Sweden, Biotage has expanded its capabilities significantly through strategic acquisitions, most notably the 2024 acquisition of Astrea Bioseparations, which has strengthened its position in the bioprocessing sector, especially in biologics and advanced therapeutics such as cell and gene therapies. This acquisition allowed Biotage to enhance its offerings in large molecule workflows and advanced biopharmaceutical purification technologies. In 2024, Biotage reported strong financial performance with revenues exceeding SEK 2 billion, a 10.5% increase year-over-year, driven by growth in both its core business and the Astrea segment. The company focuses on innovation in sample preparation, drug discovery enablement across molecule types, and expanding services in bioprocessing, along with strategic initiatives to improve profitability and operational excellence. Biotage serves a diverse customer base including pharmaceutical and biotech companies, contract development and manufacturing organizations (CDMOs), diagnostics, environmental agencies, and food and agriculture sectors, with operations spanning globally including strong presence in the Americas, Europe, and Asia. The company also emphasizes recurring revenue streams from accessories, consumables, and services, which constitute over 70% of total revenue. Biotage continues to invest significantly in research and development, introducing new products such as the Biotage® Selekt ELSD for compound detection and new plasmid DNA purification workflows, positioning itself for sustained growth aligned with emerging scientific modalities and market demands. Recent leadership changes include an interim CEO appointment while continuing strategic reviews and integrations to optimize business synergies and maximize growth potential. Overall, Biotage AB is a leading solutions partner in life sciences, providing critical technologies that span from early drug discovery through to large-scale biopharmaceutical manufacturing and analytical testing workflows worldwide.